Buy Wockhardt, target Rs 780: Reliance Securities
ETMarkets.com|
Nov 06, 2017, 10.59 AM IST
Vikas Jain, Sr. Research Analyst of Reliance Securities has a buy call on Wockhardt with a target price of Rs 780.
The current market price of Wockhardt is Rs 705.
Time period given by the analyst is one month when Wockhardt price can reach defined target.
Vikas Jain recommended to keep a stop loss at Rs 610.
In a report, the analyst said, "The stock rose to five and half month high after recovering from its 52-week low of Rs 531 and settled above its long-term moving average 200-day SMA, which is a positive signal. Bullish divergence of key technical indicators-RSI and MACD w.r.t. prior fall in price is signaling that the stock is out of previous negative momentum."
Wockhardt, incorporated in the year 1999, is a Mid Cap company (having a market cap of Rs 7,481.26 Crore) operating in Pharmaceuticals and health care sector.
Wockhardt key Products/Revenue Segments include Pharmaceuticals which contributed Rs 2,146 Crore to Sales Value (93.40 per cent of Total Sales), Licence Fees which contributed Rs 114.41 Crore to Sales Value (4.97 per cent of Total Sales), Sale of services which contributed Rs 37.11 Crore to Sales Value (1.61 per cent of Total Sales)for the year ending 31-Mar-2017.
The current market price of Wockhardt is Rs 705.
Time period given by the analyst is one month when Wockhardt price can reach defined target.
Vikas Jain recommended to keep a stop loss at Rs 610.
In a report, the analyst said, "The stock rose to five and half month high after recovering from its 52-week low of Rs 531 and settled above its long-term moving average 200-day SMA, which is a positive signal. Bullish divergence of key technical indicators-RSI and MACD w.r.t. prior fall in price is signaling that the stock is out of previous negative momentum."
Wockhardt, incorporated in the year 1999, is a Mid Cap company (having a market cap of Rs 7,481.26 Crore) operating in Pharmaceuticals and health care sector.
Wockhardt key Products/Revenue Segments include Pharmaceuticals which contributed Rs 2,146 Crore to Sales Value (93.40 per cent of Total Sales), Licence Fees which contributed Rs 114.41 Crore to Sales Value (4.97 per cent of Total Sales), Sale of services which contributed Rs 37.11 Crore to Sales Value (1.61 per cent of Total Sales)for the year ending 31-Mar-2017.